Compare Nuvalent Inc (NUVL) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Sibanye Stillwater Ltd — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Sibanye Stillwater Ltd trades at $8.66 (market cap $5.66B). The key difference: Nuvalent Inc is the larger of the two by market cap, and Sibanye Stillwater Ltd pays a 3.89% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| NUVL | SBSW | |
|---|---|---|
Market Cap | $9.81B | $5.66B |
Sector | Technology | Basic Materials |
52-Week High | $123.96 | $21.12 |
52-Week Low | $72.16 | $7.27 |
Enterprise Value | $8.52B | $7.28B |
Dividend Yield | — | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
SBSW trades at $8.59, up 7.38% today, but remains in a bearish technical trend with negative profitability metrics. The company reported a net loss of $7.30B in 2024 despite $112.13B revenue, though 2025 projections show improved EBITDA of $21.4B. Analyst consensus is mixed with 42.9% buy ratings and a $14.25 price target, representing 66% upside potential from current levels.
The stock presents a high-risk turnaround opportunity with deep value characteristics (P/E 4.76, P/S 0.72) but faces significant execution risks amid negative ROE and ROA. Key catalysts include management's debt reduction targets and operational improvements, while commodity price volatility remains a major headwind for the mining company.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
